Roche later made changes to the trial design, although the company said overall results support further testing.

Roche Holding has one of the most promising treatments for Alzheimer’s in clinical trials. The drug is several years away ...

The transaction, seen as a vote of confidence, has put the focus on other drug firms testing similar barrier-bridging ...

Roche put forward new data on two of its upcoming, non-invasive blood tests designed to help rule out a diagnosis of ...

The trial data showed that the company’s Elecsys amyloid plasma panel could rule out Alzheimer’s with a negative predictive ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

New data highlight the potential of the Roche Elecsys® Amyloid Plasma Panel and Elecsys ptau181 for ruling out Alzheimer’s ...

Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the mid-stage study has been tied to one death. | Early data suggest ...

An Alzheimer’s drug from Roche cleared a protein that’s a hallmark of the disease from patients’ brains, suggesting the drug ...

An experimental Alzheimer’s therapy from Roche successfully cleared a protein that’s a hallmark of the disease from patients’ ...

Two blood tests currently in development have shown 'very high accuracy' in detecting tell-tale signs of Alzheimer's disease, ...

New data highlight the potential of the Roche Elecsys® Amyloid Plasma Panel and Elecsys ptau181 for ruling out Alzheimer's disease related amyloid pathology with very good accuracy. In the ...